Quick Answer
Eloxx Pharmaceuticals, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
Eloxx Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 -100.0% |
$6.36M | $0.00 | — | — | — |
| Net Income | -$6.00M -90.7% |
-$3.14M +81.6% |
-$17.05M +52.7% |
-$36.06M +46.0% |
-$66.73M -93.0% |
-$34.58M +32.0% |
| Diluted EPS | -$0.49 +41.7% |
-$0.84 +87.3% |
-$6.63 +60.2% |
-$16.65 +56.4% |
-$38.15 | — |
| Total Assets | $5.27M +77.1% |
$2.98M +73.8% |
$1.71M -91.9% |
$21.12M -53.2% |
$45.14M +70.5% |
$26.48M -55.1% |
| Cash and Equivalents | $4.79M +4210.8% |
$111.0K -90.2% |
$1.13M -94.1% |
$19.21M -54.6% |
$42.27M +71.3% |
$24.67M +9.7% |
| Long-Term Debt | $0.00 | $0.00 -100.0% |
$1.61M -81.2% |
$8.56M -28.7% |
$12.00M +88.1% |
$6.38M -39.3% |
| Stockholders Equity | -$11.91M +51.1% |
-$24.34M -7.7% |
-$22.60M -112.0% |
-$10.66M -147.6% |
$22.38M +118.8% |
$10.23M -71.8% |
| R&D Expense | — | — | — | — | — | $14.59M -44.6% |
| Operating Income | -$6.44M -160.9% |
-$2.47M +85.7% |
-$17.29M +49.8% |
-$34.42M +47.9% |
-$66.02M -97.3% |
-$33.45M +33.8% |
| Shares Outstanding | 4.79M +35.5% |
3.53M +12.4% |
3.14M +45.1% |
2.17M +0.0% |
2.17M -94.6% |
40.16M +0.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | December 31, 2012 | $0.00 | -100.0% | -100.0% |
| Net Income | September 30, 2023 | -$3.59M | +52.2% | +17.3% |
| Diluted EPS | September 30, 2023 | -$1.31 | +62.2% | +33.2% |
| Total Assets | September 30, 2023 | $6.04M | -77.5% | +0.8% |
| Cash and Equivalents | September 30, 2023 | $4.78M | -80.6% | +10.3% |
| Long-Term Debt | September 30, 2023 | $2.62M | -73.4% | -21.4% |
| Stockholders Equity | September 30, 2023 | -$20.05M | -302.4% | -7.8% |
| R&D Expense | March 31, 2021 | $4.07M | -14.6% | +26.1% |
| Operating Income | September 30, 2023 | -$3.64M | +49.1% | +12.1% |
| Shares Outstanding | September 30, 2023 | 2.17M | -97.5% | +0.0% |
- Eloxx Pharmaceuticals, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
- Eloxx Pharmaceuticals, Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- Eloxx Pharmaceuticals, Inc. reported Net Income of -$6.00 million for fiscal year 2025.
- Eloxx Pharmaceuticals, Inc. showed a decrease of -90.7% in Net Income compared to the prior fiscal year.
- Eloxx Pharmaceuticals, Inc. reported Diluted EPS of $0.49 per share (loss) for fiscal year 2025.
- Eloxx Pharmaceuticals, Inc. showed an increase of +41.7% in Diluted EPS compared to the prior fiscal year.
- Eloxx Pharmaceuticals, Inc. reported Total Assets of $5.27 million for fiscal year 2025.
- Eloxx Pharmaceuticals, Inc. showed an increase of +77.1% in Total Assets compared to the prior fiscal year.
- Eloxx Pharmaceuticals, Inc. reported Cash and Equivalents of $4.79 million for fiscal year 2025.
- Eloxx Pharmaceuticals, Inc. showed an increase of +4210.8% in Cash and Equivalents compared to the prior fiscal year.
- Eloxx Pharmaceuticals, Inc. reported Long-Term Debt of $0.00 for fiscal year 2025.
- Eloxx Pharmaceuticals, Inc. reported Stockholders Equity of -$11.91 million for fiscal year 2025.
- Eloxx Pharmaceuticals, Inc. showed an increase of +51.1% in Stockholders Equity compared to the prior fiscal year.
- Eloxx Pharmaceuticals, Inc. reported R&D Expense of $14.59 million for fiscal year 2020.
- Eloxx Pharmaceuticals, Inc. showed a decrease of -44.6% in R&D Expense compared to the prior fiscal year.
- Eloxx Pharmaceuticals, Inc. reported Operating Income of -$6.44 million for fiscal year 2025.
- Eloxx Pharmaceuticals, Inc. showed a decrease of -160.9% in Operating Income compared to the prior fiscal year.
- Eloxx Pharmaceuticals, Inc. reported Shares Outstanding of 4.79 million shares for fiscal year 2025.
- Eloxx Pharmaceuticals, Inc. showed an increase of +35.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: